Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Kura Oncology reported updated Phase 1a data from the FIT-001 trial showing an objective response rate of up to 50% and median progression-free survival of 13 months for darlifarnib plus cabozantinib in pre-treated ccRCC patients. The combination demonstrated a manageable safety profile consistent with the individual agents, with activity comparing favorably to historical monotherapy benchmarks.
Key figures
- Drug Name
- darlifarnib plus cabozantinib
- Phase Of Trial
- Phase 1a
- Orr
- 33% to 50%
- Pfs
- 13 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.